Gastro-Entero-Pancreatic Tumors – PET Clinics

• Squires M.H.
• Volkan Adsay N.
• Schuster D.M.
• et al.

Octreoscan versus FDG-PET for neuroendocrine tumor staging: a organic strategy.

Ann Surg Oncol. 2015; 22: 2295-2301

• Alevroudis E.
• Spei M.E.
• Chatziioannou S.N.
• et al.

Scientific utility of 18F-FDG pet in neuroendocrine tumors previous to peptide receptor radionuclide remedy: a scientific overview and meta-analysis.

Cancers. 2021; 13: 1813

• Bösch F.
• Ghadimi M.
• Angele M.Okay.

Personalisierte resektionsverfahren bei neuroendokrinen neoplasien des pankreas [Personalised surgical therapy for neuroendocrine neoplasia of the pancreas].

Zentralblatt für Chirurgie. 2022; 147: 264-269

• Tsoli M.
• Chatzellis E.
• Koumarianou A.
• et al.

Present greatest observe within the administration of neuroendocrine tumors.

Ther Adv Endocrinol Metab. 2018; 10 (204201881880469)

• Dasari A.
• Shen C.
• Halperin D.
• et al.

Tendencies within the incidence, prevalence, and survival outcomes in sufferers with neuroendocrine tumors in the US.

JAMA Oncol. 2017; 3: 1335-1342

• Chen S.H.
• Chang Y.C.
• Hwang T.L.
• et al.

68Ga-DOTATOC and 18F-FDG PET/CT for figuring out the first lesions of suspected and metastatic neuroendocrine tumors: a potential research in Taiwan.

J Formos Med Assoc. 2018; 117: 480-487

• Lussey-Lepoutre C.
• Hindié E.
• Montravers F.
• et al.

The present function of 18F-FDOPA PET for neuroendocrine tumor imaging.

Médecine Nucléaire. 2016; 40: 20-30

• Gray N.
• Silosky M.
• Lieu C.H.
• et al.

Present standing and way forward for focused peptide receptor radionuclide positron emission tomography imaging and remedy of gastroenteropancreatic-neuroendocrine tumors.

World J Gastroenterol. 2022; 28: 1768-1780

Rules and utility of molecular imaging for personalised medication and guiding interventions in neuroendocrine tumors.

Diagn Ther Nucl Med Neuroendocrine Tumors. 2016; : 219-238https://doi.org/10.1007/978-3-319-46038-3_10

• Panagiotidis E.
• Alshammari A.
• Michopoulou S.
• et al.

Comparability of the influence of 68 Ga-DOTATATE and 18F-FDG PET/CT on medical administration in sufferers with neuroendocrine tumors.

J Nucl Med. 2016; 58: 91-96

• Kayani I.
• Bomanji J.B.
• Groves A.
• et al.

Practical imaging of neuroendocrine tumors with mixed PET/CT utilizing 68 Ga-DOTATATE (DOTA-dphe1,tyr3-octreotate) and 18F-FDG.

Most cancers. 2008; 112: 2447-2455

• Binderup T.
• Knigge U.
• Loft A.
• et al.

18F-fluorodeoxyglucose positron emission tomography predicts survival of sufferers with neuroendocrine tumors.

Clin Most cancers Res. 2010; 16: 978-985

• Papadakis G.Z.
• Karantanas A.H.
• Marias Okay.
• et al.

Present standing and future prospects of PET-imaging purposes in sufferers with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Eur J Radiol. 2021; 143: 109932

• Hicks R.J.
• Kwekkeboom D.J.
• Krenning E.
• et al.

ENETS consensus pointers for the requirements of care in neuroendocrine neoplasms: peptide receptor radionuclide remedy with radiolabelled somatostatin analogues.

Neuroendocrinology. 2017; 105: 295-309

• Strosberg J.
• El-Haddad G.
• Wolin E.
• et al.

Part 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.

N Engl J Med. 2017; 376: 125-135

• Strosberg J.R.
• Caplin M.E.
• Kunz P.L.
• et al.

177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in sufferers with midgut neuroendocrine tumours (NETTER-1): closing general survival and long-term security outcomes from an open-label, randomised, managed, section 3 trial.

Lancet Oncol. 2021; 22: 1752-1763

• Kayani I.
• Conry B.G.
• Groves A.M.
• et al.

A comparability of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

J Nucl Med. 2009; 50: 1927-1932

• Nilica B.
• Waitz D.
• Stevanovic V.
• et al.

Direct comparability of 68Ga-DOTA-TOC and 18F-FDG PET/CT within the follow-up of sufferers with neuroendocrine tumour handled with the primary full peptide receptor radionuclide remedy cycle.

Eur J Nucl Med Mol Imaging. 2016; 43: 1585-1592

• Chan D.L.
• Pavlakis N.
• Schembri G.P.
• et al.

Twin somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.

Theranostics. 2017; 7: 1149-1158

• Werner R.A.
• Solnes L.B.
• Javadi M.S.
• et al.

SSTR-RADS model 1.0 as a reporting system for SSTR PET imaging and collection of potential PRRT candidates: a proposed standardization framework.

J Nucl Med. 2018; 59: 1085-1091

• Severi S.
• Nanni O.
• Bodei L.
• et al.

Position of 18FDG PET/CT in sufferers handled with 177Lu-DOTATATE for superior differentiated neuroendocrine tumours.

Eur J Nucl Med Mol Imaging. 2013; 40: 881-888

• Weich A.
• Werner R.A.
• Serfling S.E.
• et al.

Rechallenge with extra doses of 177Lu-DOTATOC after failure of upkeep remedy with chilly somatostatin analogs.

Clin Nucl Med. 2022; 47: 719-720

Salvage peptide receptor radionuclide remedy in sufferers with progressive neuroendocrine tumors: systematic overview and meta-analysis.

Nucl Med Commun. 2020; 42: 451-458

• Rodrigues M.
• Winkler Okay.Okay.
• Svirydenka H.
• et al.

Lengthy-term survival and worth of 18F-FDG PET/CT in sufferers with gastroenteropancreatic neuroendocrine tumors handled with second peptide receptor radionuclide remedy course with 177Lu-DOTATATE.

Life. 2021; 11: 198

• Lapa C.
• Werner R.A.
• Herrmann Okay.

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography.

Endocrine. 2016; 51: 556-557